Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 53

1.

LBA2Investigation of non-V600 BRAF mutations commonly found in NSCLC for their sensitivity to Dabrafenib or Trametinib.

Noeparast A, Verschelden G, Umelo I, de Brakeleer S, Decoste L, Teugels E, de Greve J.

Ann Oncol. 2015 Mar;26 Suppl 2:ii36. doi: 10.1093/annonc/mdv098.2.

PMID:
25795886
2.

Detection of EGFR-TK Domain-activating Mutations in NSCLC With Generic PCR-based Methods.

Shahi RB, De Brakeleer S, De Grève J, Geers C, In't Veld P, Teugels E.

Appl Immunohistochem Mol Morphol. 2015 Mar;23(3):163-71. doi: 10.1097/PDM.0000000000000035.

PMID:
25751592
3.

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.

De Grève J, Moran T, Graas MP, Galdermans D, Vuylsteke P, Canon JL, Schallier D, Decoster L, Teugels E, Massey D, Chand VK, Vansteenkiste J.

Lung Cancer. 2015 Apr;88(1):63-9. doi: 10.1016/j.lungcan.2015.01.013. Epub 2015 Jan 23.

PMID:
25682316
4.

Mixed adenoneuroendocrine carcinoma of the colon: molecular pathogenesis and treatment.

Vanacker L, Smeets D, Hoorens A, Teugels E, Algaba R, Dehou MF, De Becker A, Lambrechts D, De Greve J.

Anticancer Res. 2014 Oct;34(10):5517-21.

PMID:
25275049
5.

Detection of EGFR-TK Domain-activating Mutations in NSCLC With Generic PCR-based Methods.

Shahi RB, De Brakeleer S, De Grève J, Geers C, In't Veld P, Teugels E.

Diagn Mol Pathol. 2014 Jan 30. [Epub ahead of print]

PMID:
24487311
6.

miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells.

Chen G, Umelo IA, Lv S, Teugels E, Fostier K, Kronenberger P, Dewaele A, Sadones J, Geers C, De Grève J.

PLoS One. 2013;8(3):e60317. doi: 10.1371/journal.pone.0060317. Epub 2013 Mar 26.

7.

Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.

Chen G, Noor A, Kronenberger P, Teugels E, Umelo IA, De Grève J.

PLoS One. 2013;8(3):e59708. doi: 10.1371/journal.pone.0059708. Epub 2013 Mar 18.

8.

Systematic detection of pathogenic alu element insertions in NGS-based diagnostic screens: the BRCA1/BRCA2 example.

De Brakeleer S, De Grève J, Lissens W, Teugels E.

Hum Mutat. 2013 May;34(5):785-91. doi: 10.1002/humu.22297. Epub 2013 Mar 11.

PMID:
23420552
9.

Geographical distribution of Slovenian BRCA1/2 families according to family origin: implications for genetic screening.

Krajc M, Zadnik V, Novaković S, Stegel V, Teugels E, Bešič N, Hočevar M, Vakselj A, De Grève J, Zgajnar J.

Clin Genet. 2014 Jan;85(1):59-63. doi: 10.1111/cge.12119. Epub 2013 Mar 11.

PMID:
23397983
10.

Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.

Chen G, Kronenberger P, Teugels E, Umelo IA, De Grève J.

Biochem Biophys Res Commun. 2013 Feb 15;431(3):623-9. doi: 10.1016/j.bbrc.2012.12.070. Epub 2012 Dec 22.

PMID:
23266614
11.

Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.

Lv S, Teugels E, Sadones J, De Brakeleer S, Duerinck J, Du Four S, Michotte A, De Grève J, Neyns B.

Int J Oncol. 2012 Sep;41(3):1029-35. doi: 10.3892/ijo.2012.1539. Epub 2012 Jun 29.

PMID:
22752145
12.
13.

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

De Grève J, Teugels E, Geers C, Decoster L, Galdermans D, De Mey J, Everaert H, Umelo I, In't Veld P, Schallier D.

Lung Cancer. 2012 Apr;76(1):123-7. doi: 10.1016/j.lungcan.2012.01.008. Epub 2012 Feb 10.

14.

Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma.

Lv S, Teugels E, Sadones J, Quartier E, Huylebrouck M, DU Four S, LE Mercier M, DE Witte O, Salmon I, Michotte A, DE Grève J, Neyns B.

Anticancer Res. 2011 Dec;31(12):4457-63.

PMID:
22199315
15.

BRCA1/2 status and clinicopathologic characteristics of patients with double primary breast and ovarian cancer.

Cvelbar M, Hocevar M, Vidmar G, Teugels E.

Neoplasma. 2011;58(3):198-204.

PMID:
21391735
16.

Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells.

Chen G, Kronenberger P, Teugels E, De Grève J.

Biol Proced Online. 2010 Nov 11;13:1. doi: 10.1186/1480-9222-13-1.

17.

Accurate KRAS mutation testing for EGFR-targeted therapy in colorectal cancer: emphasis on the key role and responsibility of pathologists.

Hoorens A, Jouret-Mourin A, Sempoux C, Demetter P, De Hertogh G, Teugels E.

Acta Gastroenterol Belg. 2010 Oct-Dec;73(4):497-503. Review.

PMID:
21299161
18.

The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population.

Stegel V, Krajc M, Zgajnar J, Teugels E, De Grève J, Hočevar M, Novaković S.

BMC Med Genet. 2011 Jan 14;12:9. doi: 10.1186/1471-2350-12-9.

19.

International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation.

Peixoto A, Santos C, Pinheiro M, Pinto P, Soares MJ, Rocha P, Gusmão L, Amorim A, van der Hout A, Gerdes AM, Thomassen M, Kruse TA, Cruger D, Sunde L, Bignon YJ, Uhrhammer N, Cornil L, Rouleau E, Lidereau R, Yannoukakos D, Pertesi M, Narod S, Royer R, Costa MM, Lazaro C, Feliubadaló L, Graña B, Blanco I, de la Hoya M, Caldés T, Maillet P, Benais-Pont G, Pardo B, Laitman Y, Friedman E, Velasco EA, Durán M, Miramar MD, Valle AR, Calvo MT, Vega A, Blanco A, Diez O, Gutiérrez-Enríquez S, Balmaña J, Ramon y Cajal T, Alonso C, Baiget M, Foulkes W, Tischkowitz M, Kyle R, Sabbaghian N, Ashton-Prolla P, Ewald IP, Rajkumar T, Mota-Vieira L, Giannini G, Gulino A, Achatz MI, Carraro DM, de Paillerets BB, Remenieras A, Benson C, Casadei S, King MC, Teugels E, Teixeira MR.

Breast Cancer Res Treat. 2011 Jun;127(3):671-9. doi: 10.1007/s10549-010-1036-3. Epub 2010 Jul 22.

PMID:
20652400
20.

Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families.

De Brakeleer S, De Grève J, Loris R, Janin N, Lissens W, Sermijn E, Teugels E.

Hum Mutat. 2010 Mar;31(3):E1175-85. doi: 10.1002/humu.21200.

PMID:
20077502
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk